Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

51 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Spartalizumab or placebo in combination with dabrafenib and trametinib in patients with BRAF V600-mutant melanoma: exploratory biomarker analyses from a randomized phase 3 trial (COMBI-i).
Tawbi HA, Robert C, Brase JC, Gusenleitner D, Gasal E, Garrett J, Savchenko A, Görgün G, Flaherty KT, Ribas A, Dummer R, Schadendorf D, Long GV, Nathan PD, Ascierto PA. Tawbi HA, et al. Among authors: gorgun g. J Immunother Cancer. 2022 Jun;10(6):e004226. doi: 10.1136/jitc-2021-004226. J Immunother Cancer. 2022. PMID: 35728875 Free PMC article.
A community-based lung cancer rapid tissue donation protocol provides high-quality drug-resistant specimens for proteogenomic analyses.
Boyle TA, Quinn GP, Schabath MB, Muñoz-Antonia T, Saller JJ, Duarte LF, Hair LS, Teer JK, Chiang DY, Leary R, Wong CC, Savchenko A, Singh AP, Charette L, Mendell K, Gorgun G, Antonia SJ, Chiappori AA, Creelan BC, Gray JE, Haura EB. Boyle TA, et al. Among authors: gorgun g. Cancer Med. 2020 Jan;9(1):225-237. doi: 10.1002/cam4.2670. Epub 2019 Nov 20. Cancer Med. 2020. PMID: 31747139 Free PMC article.
Lenalidomide for the treatment of relapsed and refractory multiple myeloma.
van de Donk NW, Görgün G, Groen RW, Jakubikova J, Mitsiades CS, Hideshima T, Laubach J, Nijhof IS, Raymakers RA, Lokhorst HM, Richardson PG, Anderson KC. van de Donk NW, et al. Among authors: gorgun g. Cancer Manag Res. 2012;4:253-68. doi: 10.2147/CMAR.S27087. Epub 2012 Aug 14. Cancer Manag Res. 2012. PMID: 22956884 Free PMC article.
Selective and potent Akt inhibition triggers anti-myeloma activities and enhances fatal endoplasmic reticulum stress induced by proteasome inhibition.
Mimura N, Hideshima T, Shimomura T, Suzuki R, Ohguchi H, Rizq O, Kikuchi S, Yoshida Y, Cottini F, Jakubikova J, Cirstea D, Gorgun G, Minami J, Tai YT, Richardson PG, Utsugi T, Iwama A, Anderson KC. Mimura N, et al. Among authors: gorgun g. Cancer Res. 2014 Aug 15;74(16):4458-69. doi: 10.1158/0008-5472.CAN-13-3652. Epub 2014 Jun 16. Cancer Res. 2014. PMID: 24934808 Free PMC article.
Lenalidomide Enhances Immune Checkpoint Blockade-Induced Immune Response in Multiple Myeloma.
Görgün G, Samur MK, Cowens KB, Paula S, Bianchi G, Anderson JE, White RE, Singh A, Ohguchi H, Suzuki R, Kikuchi S, Harada T, Hideshima T, Tai YT, Laubach JP, Raje N, Magrangeas F, Minvielle S, Avet-Loiseau H, Munshi NC, Dorfman DM, Richardson PG, Anderson KC. Görgün G, et al. Clin Cancer Res. 2015 Oct 15;21(20):4607-18. doi: 10.1158/1078-0432.CCR-15-0200. Epub 2015 May 15. Clin Cancer Res. 2015. PMID: 25979485 Free PMC article.
A novel Aurora-A kinase inhibitor MLN8237 induces cytotoxicity and cell-cycle arrest in multiple myeloma.
Görgün G, Calabrese E, Hideshima T, Ecsedy J, Perrone G, Mani M, Ikeda H, Bianchi G, Hu Y, Cirstea D, Santo L, Tai YT, Nahar S, Zheng M, Bandi M, Carrasco RD, Raje N, Munshi N, Richardson P, Anderson KC. Görgün G, et al. Blood. 2010 Jun 24;115(25):5202-13. doi: 10.1182/blood-2009-12-259523. Epub 2010 Apr 9. Blood. 2010. PMID: 20382844 Free PMC article.
Antimyeloma activity of a multitargeted kinase inhibitor, AT9283, via potent Aurora kinase and STAT3 inhibition either alone or in combination with lenalidomide.
Santo L, Hideshima T, Cirstea D, Bandi M, Nelson EA, Gorgun G, Rodig S, Vallet S, Pozzi S, Patel K, Unitt C, Squires M, Hu Y, Chauhan D, Mahindra A, Munshi NC, Anderson KC, Raje N. Santo L, et al. Among authors: gorgun g. Clin Cancer Res. 2011 May 15;17(10):3259-71. doi: 10.1158/1078-0432.CCR-10-3012. Epub 2011 Mar 23. Clin Cancer Res. 2011. PMID: 21430070 Free PMC article.
Combination of a Selective HSP90α/β Inhibitor and a RAS-RAF-MEK-ERK Signaling Pathway Inhibitor Triggers Synergistic Cytotoxicity in Multiple Myeloma Cells.
Suzuki R, Kikuchi S, Harada T, Mimura N, Minami J, Ohguchi H, Yoshida Y, Sagawa M, Gorgun G, Cirstea D, Cottini F, Jakubikova J, Tai YT, Chauhan D, Richardson PG, Munshi N, Ando K, Utsugi T, Hideshima T, Anderson KC. Suzuki R, et al. Among authors: gorgun g. PLoS One. 2015 Dec 2;10(12):e0143847. doi: 10.1371/journal.pone.0143847. eCollection 2015. PLoS One. 2015. PMID: 26630652 Free PMC article.
51 results